.png)
Mid-Size Biopharmaceutical
Outcomes Research, Market Access, Real-World Evidence
Phase III
Oncology
Subscribe to our newsletter to receive the latest case studies.
Mid-Size Biopharmaceutical
Outcomes Research, Market Access, Real-World Evidence
Phase III
Oncology
A mid-size biopharmaceutical company wanted to maximize insights from existing RWE analyses while strengthening future evidence generation for a Phase III oncology therapy.
Existing datasets required review to determine data quality, publication feasibility, and their ability to support priority value messages.
The client engaged Alkemi to assess the current analyses, identify credible publication opportunities, and develop an adaptable Medicare RWE protocol for future claims research.
1. Assessed existing datasets against the evidence landscape and future value objectives.
2. Evaluated data quality, limitations, and the messages that could be supported credibly.
3. Identified priority publication opportunities and evidence gaps.
4. Aligned cohort, treatment-line, and outcome definitions to develop an execution-ready Medicare RWE protocol.
Turn existing evidence into a clear plan for credible, future-ready RWE generation.
“Alkemi translated our evidence needs into a clear, execution-ready Medicare protocol that can support future real-world research.” - VP, Global Outcomes Research & Real-World Evidence
Clarified the strategic value and limitations of existing RWE, helping the client focus publication efforts on the most credible opportunities.
Established a rigorous, adaptable framework to accelerate future Medicare claims research.
Created a practical foundation for generating evidence on treatment patterns, utilization, costs, and outcomes.